The effect of pubertal delay by GnRH agonist in GH-deficient children on final height by Mul, D. (Dick) et al.
The Effect of Pubertal Delay by GnRH Agonist in
GH-Deficient Children on Final Height
D. MUL, J .M. WIT, W. OOSTDIJK, AND J. VAN DEN BROECK ON BEHALF OF THE DUTCH ADVISORY GROUP
ON GROWTH HORMONE
Department of Pediatrics/Subdivision Endocrinology (D.M.), Erasmus University Medical Centre/Sophia Children’s
Hospital, Rotterdam 3000 CB; Department of Pediatrics (J.M.W., W.O.), Leiden University Medical Center, Leiden 2300 RC;
and Dutch Growth Foundation (J.V.d.B.), Rotterdam 3015 GJ, The Netherlands
Several strategies can be applied to optimize GH treatment
in GH-deficient (GHD) children during puberty (1). In a
recent issue of JCEM, Mericq et al. (2) reported their results
of a prospective, randomized trial on the effect of GH alone
or in combination with GnRH agonist (GnRHa) in pubertal
GHD patients. They concluded that delaying puberty by
GnRHa led to a near final height (FH) sd score of1.3 0.5
compared with 2.7  0.3 in the group treated with GH
alone. However, in this study, the patients had been un-
treated up to the age of 12–18.5 yr, which is unusual for
western countries. In addition, in several cases the growth
retardation was less severe than would be expected in clas-
sical GHD patients without treatment.
Although a randomized controlled trial in a large and
representative sample is certainly the best design to study the
efficacy of a therapeutical regimen, a patient series with
matched controls is a good second. We report on a retro-
spective analysis of the effect of the addition of GnRHa
(shortly after the onset of puberty) to GH treatment in GHD
children. Matched controls with GH treatment were used for
comparison. The children were younger as well as shorter for
age compared with the subjects in the randomized trial (2).
Patients and Methods
We selected from the nationwide database (n  762) of GH-treated
children (Dutch Growth Foundation/Advisory Group on Growth Hor-
mone) 21 GHD patients who had reached FH and had been treated with
the combination of GH and GnRHa (Triptorelin or Leuprolide acetate,
3.75 mg per month), after a variable period of GH therapy alone. GnRHa
was given soon after entering into puberty at a relatively early age
and/or low height for age.
Thereafter the database was screened for matched controls who were
treated with GH only. Matching criteria included sex and height sd score
at the start of puberty. These parameters were chosen to minimize
probable confounding effects of differences in age and height sd score
at the start of puberty between males and females. For 8 patients on the
combination therapy (group A) suitable matched controls were found
(group B). For the remaining 13 patients (group C) no suitable controls
were available.
In a separate analysis (data not shown) patients and controls were
matched using seven variables (age at the start of puberty, height sd
score, and age at the start of GH treatment, GH dosage, sex, body mass
index sd score at the start of GH treatment, and type of GH deficiency)
where as much as possible variables were matched simultaneously. This
strategy, however, led to different numbers of boys and girls in the two
groups, because the best matching was found between different sexes in
some cases.
We used as outcome parameters FH sd score, FH sd score-midpar-
ental height (MPH) sd score and FH sd score-height sd score at the start
of puberty. In a multiple regression analysis of groups A and C these
three outcome parameters were used as dependent variables. The age at
the start of puberty minus the population mean for sex (3), height sd
score at the start of puberty, GH dose and duration of GnRHa treatment
were used as independent variables.
Results
Selected clinical data are shown in Table 1 [mean (sd)]. In
groups A and C, the mean age at the start of GnRHa treat-
ment was 12.8 (1.8) and 12.0 (1.9) yr, respectively, and the
mean treatment period was 2.7 (range, 1.8–4.0) and 3.1
(range, 1.1–5.6) yr, respectively. The mean difference be-
tween the observed age at onset of puberty and the norma-
tive value was 1.2, 0.8, and 0.1 yr in groups A, B, and C,
respectively.
In the analysis using seven matching variables we found
comparable results for the outcome parameters, with a sig-
nificant difference in FH sd score-MPH sd score between
children treated with GH and GnRHa and their matched
controls.
In the multiple regression analysis a significant negative
correlation of height sd score at the start of puberty with the
difference between FH sd score and height sd score at the
start of puberty was observed (P  0.01). No significant
correlation was demonstrated for FH sd score or the differ-
ence between FH sd score and MPH sd score as dependent
variables.
Discussion
We conclude that GHD patients who are at risk of not
attaining their genetic growth potential by the relatively
early onset of puberty can reach a FH close to their genetic
target by the addition of GnRHa to GH substitution therapy.
This effect was seen in both groups A and C. In contrast,
continuing GH therapy alone, as in group B, leads to a FH
of approximately 1 sd below target. The efficacy of the com-
bination therapy is also shown by other relevant parameters
such as the greater mean change in height sd score from the
onset of puberty and, to a lesser extent, the change in height
sd score since the onset of GH treatment. If the difference
between FH sd score and MPH sd score is taken as the most
Abbreviations: FH, Final height; GHD, GH-deficient; GnRHa, GnRH
agonist; MPH, midparental height.
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reliable outcome parameter, the effect of GnRHa addition on
FH can be estimated at 1 sd score (approximately 6–7 cm).
The literature on the final effect of the addition of GnRHa
to GH in GHD children is limited. Adan et al. (4) reported that
the combined treatment resulted in a normal adult height,
albeit somewhat below target height. Hibi et al. (5) reported
in 24 GHD children treated with GH and cyproterone acetate
and/or medroxyprogesterone acetate for 4.4 yr that FH sd
score was about 1 sd score higher than in a group children
on GH alone. The FH sd score was 2.2 in boys and 1.9 in
girls, somewhat lower than in the more recent studies. This
may be due to less effective gonadal suppression by cypro-
terone acetate or medroxyprogesterone acetate (5).
In summary, despite the uncertainty about the represen-
tativeness of the patient sample studied by Mericq et al. (2),
their data and those of other investigators discussed here, as
well as our retrospective analysis, all point in one direction:
adding GnRHa in early puberty to GHD patients who have
been treated with GH, or in whom GH and GnRHa are
started simultaneously, enables the patients to reach their
genetic target, whereas FH of patients on GH alone is about
1 sd score below MPH sd score. This result is of similar size
as the efficacy of GnRHa in idiopathic short stature (6).
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TABLE 1. Summary of the clinical data [mean (SD)]
Group A (n  8) Group B (n  8) Group C (n  13)
Number (M/F) 5/3 5/3 0/13
Diagnosis
Multiple/isolated GH deficiency 5/3 7/1 8/5
Idiopathic/organic GH deficiency 6/2 6/2 5/8
GH peak (mU/liter) 10.2 (5.4) 6.6 (6.0) 8.5 (4.8)
MPH SD score 1.92 (0.81) 0.89 (1.08) 1.36 (1.22)
Age at start GH (yr) 8.9 (4.3) 6.8 (3.7) 9.0 (4.1)
H SD score start GH 4.10 (1.43) 3.78 (1.60) 3.43 (1.97)
Age at start puberty (yr) 12.2 (2.2) 11.8 (1.3) 10.4 (2.4)
H SD score at start puberty 3.02 (1.46) 1.97 (1.19) 2.68 (1.90)
GH dosage during pubertya 17.4 (2.8) 14.6 (4.9) 16.0 (3.8)
FH SD score 1.75 (0.89) 1.89 (1.16) 1.34 (0.95)
FH SD score—MPH SD score 0.18 (0.86)b 0.99 (1.25) 0.03 (1.19)
FH SD score—H SD score start puberty 1.27 (1.81) 0.08 (1.08) 1.34 (1.79)
a GH dosage: average in pubertal period (IU/m2  week, 1 mg  3 IU).
b P  0.05 compared with group B; in other variables, no significant differences between groups A and B.
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